Publications by authors named "David A Reardon"

Claim this Profile
P
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma.
Gilbert Youssef, Elisa Aquilanti, Julie J Miller, Zhou Lan, Aleksandra B Lasica, David A Reardon

Neuro Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.
Emilie Le Rhun, Debaleena Sain, Sara C Erridge, David A Reardon, Giuseppe Minniti

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.
Martin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, Norbert Galldiks, Nathalie L Albert, David A Reardon

Neuro Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.
Aleksandra B Lasica, Zhou Lan, Julie J Miller, Albert Jiao, Ian Pan, David A Reardon

Neuro Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.
Alexander L Ling, Jennifer Gantchev, Michael C Prabhu, Sreyashi Basu, Ryuhjin Ahn, David A Reardon

Sci Transl Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.
Rupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, Can Ilgın, Manmeet S Ahluwalia, David A Reardon

Neuro Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
James R Whittle, Maria Vieito, Kristoffer Rohrberg, Maria E Rodriguez-Ruiz, Eduardo Castanon, David A Reardon

Neurooncol Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions.
Brian M Andersen, Camilo Faust Akl, Michael A Wheeler, Zhaorong Li, Martin Diebold, David A Reardon

Nature· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
Patrick Y Wen, Michael Weller, Eudocia Q Lee, Mehdi Touat, Mustafa Khasraw, David A Reardon

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.
Camilo Faust Akl, Brian M Andersen, Zhaorong Li, Federico Giovannoni, Martin Diebold, David A Reardon

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
Macarena I de la Fuente, Mehdi Touat, Martin J van den Bent, Matthias Preusser, Katherine B Peters, David A Reardon

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seizure characteristics and outcomes in patients with pleomorphic xanthoastrocytoma.
Daniel J Zhou, Colin A Ellis, Kevin Xie, Nishant Sinha, Sharon X Xie, David A Reardon

Neurooncol Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
Georgina V Long, Elena Shklovskaya, Laveniya Satgunaseelan, Yizhe Mao, Inês Pires da Silva, David A Reardon

Nat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth, David A Reardon

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Marjolein Geurts, Luzia Berchtold, Franz Koenig, Burt Nabors, David A Reardon

Neurooncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.
Kenny K H Yu, Sreyashi Basu, Gerard Baquer, Ryuhjin Ahn, Jennifer Gantchev, David A Reardon

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
lioma esource utreach ith upport: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patients.
Rachel Garcia Fox, Ugonma N Chukwueke, Timothy Sannes, Damien Miran, Daniel Chiu, David A Reardon

Neurooncol Pract· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.
Alice Talpin, Ana Maia, Jean-Marie Carpier, Guillaume Kulakowski, Lucie Aubergeon, David A Reardon

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting.
Levon Demirdjian, Spyros Triantos, Kristopher Standish, Shibu Thomas, Qi Xia, David A Reardon

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Benjamin M Ellingson, Francesco Sanvito, Whitney B Pope, Timothy F Cloughesy, Raymond Y Huang, David A Reardon

AJNR Am J Neuroradiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients.
J Bryan Iorgulescu, Timothy Blewett, Kan Xiong, Andjela Crnjac, Ruolin Liu, David A Reardon

Clin Chem· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of deep learning and radiomic signatures for overall survival prediction in recurrent high-grade glioma treated with immunotherapy.
Qi Wan, Clifford Lindsay, Chenxi Zhang, Jisoo Kim, Xin Chen, David A Reardon

Cancer Imaging· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
J Ricardo McFaline-Figueroa, Lu Sun, Gilbert C Youssef, Raymond Huang, Gang Li, David A Reardon

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.
Tyler A Lanman, Gilbert Youssef, Raymond Huang, Rifaquat Rahman, Matthew DeSalvo, David A Reardon

Neurooncol Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Joe S Mendez, Adam L Cohen, Midori Eckenstein, Randy L Jensen, Lindsay M Burt, David A Reardon

Neurooncol Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis